leukaemia Archives -

Roche and AbbVie’s Venclexta approved in CLL

George Underwood AbbVie, CLL, Genentech, leukaemia, Roche, Venclexta, venetoclax 0 Comment

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for

Roche and AbbVie’s Venclexta approved in CLL

https://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/

News/ News/ R&D

Scotland says no to Yescarta, but backs Kymriah

Phil Taylor Kymriah, leukaemia, SMC, Yescarta 0 Comment

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types

Scotland says no to Yescarta, but backs Kymriah

https://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/

News/ News/ R&D

AbbVie, Roche eye first-line use of Venclexta in leukaemia

Phil Taylor AbbVie, leukaemia, R&D, Roche, Venclexta 0 Comment

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into

AbbVie, Roche eye first-line use of Venclexta in leukaemia

https://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/

News/ News/ Oncology/ Top stories

Cancer Research UK gives $4m funding to Glasgow Uni CML project

Piotr Wnuk Cancer Research UK, chronic myeloid leukaemia, epigenetics, leukaemia 0 Comment

Cancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to

Cancer Research UK gives $4m funding to Glasgow Uni CML project

https://pharmaphorum.com/news/experimental-leukaemia-study-grant/

Market Access/ News/ News/ News/ News/ Oncology/ R&D/ US

FDA grants leukaemia drug ‘breakthrough’ status

Joy Persaud acute myeloid leukaemia, Daiichi Sankyo, fda, leukaemia, Oncology, quizartinib 0 Comment

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator. Daiichi Sankyo announced that

FDA grants leukaemia drug ‘breakthrough’ status

https://pharmaphorum.com/market-access-2/fda-grants-leukaemia-drug-breakthrough-status/

Cancer/ News/ UK & Europe

Pfizer objects to NICE methods in leukaemia drug rejection

Richard Staines ALL, blood cancer, leukaemia, market access, NICE, Pfizer 0 Comment

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the

Pfizer objects to NICE methods in leukaemia drug rejection

https://pharmaphorum.com/news/pfizer-questions-nice-methods-besponsa/

Cancer/ News

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

Andrew McConaghie ASCO17, CAR T, chronic lymphocytic leukaemia, leukaemia, Novartis 0 Comment

A combination of Novartis’ ‘next generation’ CAR-T drug CTL119 with Janssen and AbbVie’s Imbruvica has cleared all signs

Spectacular early results for Novartis’ CAR-T combined with Imbruvica

https://pharmaphorum.com/news/spectacular-early-results-novartis-car-t-combined-imbruvica/

News/ Teva/ UK & Europe

Teva’s Trisenox approved in first line for APL

Richard Staines Acute Promyelocytic Leukaemia, blood cancer, cancer, leukaemia, Teva 0 Comment

First ever chemotherapy-free regimen for rare leukaemia.

Teva’s Trisenox approved in first line for APL

https://pharmaphorum.com/news/tevas-trisenox-approved-first-line-apl/

News/ US

Gamida Cell’s cell therapy treatment gains breakthrough status

Richard Staines Biotech, bone marrow, cancer, Gamida Cell, leukaemia 0 Comment

Regulator to expedite review of blood cancer treatment

Gamida Cell’s cell therapy treatment gains breakthrough status

https://pharmaphorum.com/news/gamida-cells-nicord-breakthrough/

Trending

leukaemia

Login